News

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Kalkine Media4d
Is Institutional Growth Pointing to Broader Awareness of Bausch + Lomb (NYSE:BLCO)?
Highlights,Commonwealth Equity Services LLC initiated a new position in Bausch + Lomb during the fourth quarter.,Firms ...
Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
American Association of Individual Investors6d
Which Is a Better Investment, Bausch + Lomb Corporation or Penumbra, Inc. Stock?
Learn more about whether Bausch + Lomb Corporation or Penumbra, Inc. is a better investment based on AAII's A+ Investor ...
3B Media News7d
BAUSCH AND LOMB ANNOUNCES ENVISTA LENS IMPLANT PRODUCTS RECALL
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst ...
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses in the U.S.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) ...
Bausch + Lomb Stock Sinks on 'Voluntary Recall' of Some Implantable Eye Lenses
Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of ...
Hosted on MSN18d
Wells Fargo Downgrades Bausch + Lomb (BLCO)
Fintel reports that on March 28, 2025, Wells Fargo downgraded their outlook for Bausch + Lomb (NYSE:BLCO) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 32.58% Upside As of March ...